June 30, 2020 / 11:55 AM / 3 days ago

BRIEF-Oncternal Therapeutics Announces Increased Focus Of Antibody Program On Mantle Cell Lymphoma

June 30 (Reuters) - Oncternal Therapeutics Inc:

* ONCTERNAL THERAPEUTICS ANNOUNCES INCREASED FOCUS OF THE CIRMTUZUMAB ROR1 ANTIBODY PROGRAM ON MANTLE CELL LYMPHOMA

* ONCTERNAL THERAPEUTICS INC - MEETING REQUESTED WITH FDA TO DISCUSS REGISTRATION PATHWAY FOR CIRMTUZUMAB FOR PATIENTS WITH MCL

* ONCTERNAL THERAPEUTICS INC - INCREASING PLANNED ENROLLMENT OF PATIENTS WITH MCL IN ONGOING CIRLL PHASE 1/2 CLINICAL TRIAL OF CIRMTUZUMAB WITH IBRUTINIB

* ONCTERNAL THERAPEUTICS INC - PLANS TO FURTHER EXPLORE CLINICAL COMBINATION STRATEGIES FOR CIRMTUZUMAB FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below